NeuroSearch selected QCTR in 2007 as the CRO to run MermaiHD, a phase III clinical trial in Huntington's disease. One of the main reasons for selecting QCTR was their in-depth therapeutic knowledge in the field and that they, despite their relatively small size, were prepared to take on the full study management with a well-defined, tried-and-tested network of subcontractors.
QCTR's attention to the MermaiHD study has been outstanding and has exceeded our expectations. In particular we have appreciated their pro-active approach, low turn-over in the study team, good communication and excellent overview over the study processes, which together has allowed timely solutions for upcoming issues all the way from feasibility to report writing.
Åsa Rembratt, Ph.D.
Head of Clinical Development
The work that QCTR has brought to our team has been interesting and challenging and allowed us to contribute to current clinical research in Huntington’s Disease, an area of real unmet medical need.
It is a pleasure to work with QCTR CRAs who are well informed about the study, highly supportive and very professional in all their dealings with us at site.
Dr Hugh Rickards MD FRCPsych
Consultant in Neuropsychiatry
Hon. Reader in Neuropsychiatry
The Barberry, Birmingham, UK